Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.18 USD | +1.80% | -2.35% | +1.46% |
05:34pm | Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study | MT |
May. 06 | Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $156,000 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.46% | 2.6B | |
+29.37% | 49.18B | |
+1.02% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.65% | 18.71B | |
+8.10% | 13.26B | |
+32.23% | 12.32B | |
-0.91% | 11.99B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Celldex Therapeutics Q4 Loss Widens, Revenue Rises; Shares Up Pre-Bell